India Hits the Jackpot Amidst US Tariff War: Europe Opens Doors for Indian Medicines; Exports Get the Green Light
Amidst tariff tensions with the US, Europe has opened its doors to Indian pharmaceutical companies. The Central Drugs Standard Control Organization (CDSCO) has granted written approval to several Indian companies to export Active Pharmaceutical Ingredients (APIs)—the raw materials used in medicines—to the European Union (EU). This means these companies can now export APIs used in treating cancer, infections (requiring antibiotics), and other serious ailments, while adhering to Europe’s stringent quality standards.
Conditions for Approval Granted to Indian Companies
The CDSCO has clarified that even after receiving approval, all companies must consistently adhere to quality standards. If any discrepancies are found during inspections, if drug quality falls below standards, or if irregularities surface in reports from local or international regulators, the authorities must be informed within seven days. In the event of a rule violation, this approval can be immediately suspended or revoked.
Benefits of This Agreement for India and Europe
The elimination of taxes on medicines and medical devices will make Indian generic medicines more affordable and competitive in Europe. Additionally, administrative costs will decrease, and simplified regulations will accelerate the approval process for medicines in Europe compared to the past.
Indian Companies Granted Approval for Exports to Europe
Companies that have received approval to export APIs to the European Union include Honor Lab Limited (Telangana), Ravi Biolife Private Limited (Maharashtra), and Unimax Chemicals Private Limited (Maharashtra).
